Overview

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Status:
Not yet recruiting

Trial end date:
2023-03-03

Target enrollment:

Participant gender:

Summary

The study is a multicenter, open-label, randomized controlled clinical study. The purpose of the study is to evaluate the efficacy and safety of apatinib combined with chemotherapy versus chemotherapy in second-line gastric cancer receiving prior anti-PD-1 therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Wuhan Union Hospital, China

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib